Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials
Leuk Lymphoma
.
2023 Jul-Aug;64(7):1340-1343.
doi: 10.1080/10428194.2023.2209682.
Epub 2023 May 11.
Authors
Poorva Bindal
1
,
Mimi Najjar
2
,
Kelly Koehn
3
,
Amandeep Godara
4
,
Douglas W Sborov
4
,
Brian McClune
4
,
Kelley Julian
4
,
Charlotte Wagner
4
,
Ghulam Rehman Mohyuddin
4
Affiliations
1
Division of Hematology and Hematological Malignancies, University of Massachusetts, Worcester, MA, USA.
2
Department of Medicine, University of Balamand, Beirut, Lebanon.
3
Mercy Health Center, Springfield, MO, USA.
4
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
PMID:
37170589
DOI:
10.1080/10428194.2023.2209682
No abstract available
Publication types
Systematic Review
MeSH terms
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / therapy
Randomized Controlled Trials as Topic